Results for tag: "Esbriet"

Esbriet is a brand of medication used to treat idiopathic pulmonary fibrosis (IPF), a chronic and progressive lung disease. It is a prescription drug that works by slowing the progression of IPF and reducing the rate of decline in lung function. Esbriet is the only approved drug for IPF in the United States and is available in tablet form. It is also approved in other countries, including Canada, Japan, and the European Union. Esbriet is part of the larger respiratory drug market, which includes medications used to treat a variety of respiratory conditions, such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. These drugs are used to reduce symptoms, improve quality of life, and slow the progression of the disease. The respiratory drug market is highly competitive, with many companies offering a variety of treatments. Some of the major players in the market include GlaxoSmithKline, AstraZeneca, Novartis, Merck, and Boehringer Ingelheim. Other companies, such as Vertex Pharmaceuticals, are also developing new treatments for respiratory diseases. Show Less Read more